Open-label Phase I Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
Price : $35 *
At a glance
- Drugs ET-190 (Primary)
- Indications Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Eureka Therapeutics
- 31 Jan 2019 Status changed from recruiting to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 05 Apr 2018 Status changed from not yet recruiting to recruiting.